Navigation Links
BC catalyst discovery promises faster, cheaper drug production

Boston College chemists have discovered a substance that will make it possible for scientists to produce scores of pharmaceuticals and other chemicals in a faster, less expensive way.

In a letter published in the Sept. 7 issue of the journal Nature, a team led by professors Amir Hoveyda and Marc Snapper of the Boston College Chemistry Department said they had found a first-of-its-kind catalyst that will eliminate several costly and wasteful steps from the process of synthesizing certain molecules.

"Our new catalyst will significantly improve the efficiency with which biologically and medicinally active molecules can be prepared," said Prof. Hoveyda, who is also chair of the department. "Such a catalyst, by shortening synthesis routes, will significantly lower cost and reduce the waste generated in laboratory syntheses."

The discovery is based on the concept of chirality, which refers to the two-handed nature of certain molecules. Many important chemical compounds that exist in nature or are created by laboratory scientists come in two, mirror-image forms ?a "left" and a "right" hand. Some drugs comprise chiral molecules, which can pose a problem: often, one hand, or enantiomer, of the drug molecule can be beneficial to a patient's health, while the other may be harmful.

Because of this, it is important for anyone who wants to prepare drugs, especially in large quantities, to be able to synthesize single-handed compounds with high selectivity; ideally, none of the opposite hand should be around. This way, the unfavorable properties of one enantiomer are eliminated without diluting the desired enantiomer's benefits.

What the Hoveyda-Snapper team discovered can be referred to as a "silylation catalyst" ?a molecule that attaches, with extremely high selectivity, a silicon atom to an alcohol group so that only one enantiomer is formed. Other molecules are known to promote this important reaction, but the new catalyst is the first t o control the handedness of the process at the same time.

"What makes this discovery enormously significant is that silyation is already one of the most useful ways ?if not the most effective way ?to protect an alcohol from undesired reactions while a molecule is being modified somewhere else," Prof. Snapper said.

Because of the new catalyst, what used to take four to five steps to accomplish ?each step adding significantly to the final cost ?can now be achieved in a single transformation. The substance also contains no metals and is therefore more environmentally friendly than many other catalysts.

"The new catalyst is easy to prepare, requires little or no solvent and therefore minimizes waste, and can be used in air and can be recycled several times," Prof. Snapper added. "Together, these properties make our discovery an important one both from the theoretical as well as the practical point of view."

"This is an elegant solution to a very important, practical problem, with the potential to result in more efficient, more environmentally friendly, and less expensive processes for manufacturing drugs. It's a great example of how NIH support for fundamental chemical research can benefit the American health care consumer," said John M. Schwab, a chemist at the National Institute of General Medical Science,which supported the work.


'"/>

Source:Boston College


Related biology news :

1. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
2. Protein discovery could unlock the secret to better TB treatment
3. Purdue proves concept of using nano-materials for drug discovery
4. UCSD discovery may help extend life of natural pesticide
5. Leprosy microbes lead scientists to immune discovery
6. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
7. Researchers make surprise discovery that some neurons can transmit three signals at once
8. Important discovery about second most fatal cancer
9. Harmless virus may hold key to more effective HIV drug discovery
10. Fundamental discovery -- Bone fracture
11. Genetic discovery could lead to drought-resistant plants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... , ... Parallel6™ , the leader in mClinical™ technologies for improving patient ... one of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma ... “We take pride in honoring Parallel6 as one of the top 10 companies that ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell ... cell technologies for neurodegenerative diseases, announced today that Chaim ... for Regenerative Medicine,s (ARM) 5 th Annual Cell & ... 09:40 EDT in Boston . ... Medical Officer & Chief Operating Officer, will participate in a ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of ... Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis ... clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of ...
Breaking Biology Technology: